COVID-19 morbidity in patients after orthotopic heart transplantation - single center clinical observation
- PMID: 33860947
- DOI: 10.32394/pe.74.51
COVID-19 morbidity in patients after orthotopic heart transplantation - single center clinical observation
Abstract
Introduction: The study is a prospective clinical observation of patients after orthotopic heart transplantation in a large academic medical center in relation to COVID-19 morbidity. The study population was comprised of 552 patients. All patients were consulted and advised by telephone as regards the prophylaxis of SARS-CoV-2 infection. Hospital and outpatient follow-ups were limited to the minimum. Preventive modification of immunosuppression was not recommended in relation to the pandemic. Three patients with multiple comorbidities (a woman aged 60, a man aged 59, and another man aged 83; 2.25 years, 5.5 years, and 7.5 years after heart transplantation, respectively) and one patient with concomitant arterial hypertension (a woman aged 48, 5.5 years after heart transplantation) presented with a symptomatic COVID-19 infection. Three of the patients were on tacrolimus immunosuppression, and both female patients were additionally on therapy with mycophenolate mofetil, which was discontinued following the diagnosis of infection. One male patient received combined therapy of cyclosporine A and mycophenolate mofetil. The 60-year-old woman presented with gastrointestinal manifestations of the COVID-19 infection which were of moderate severity. The recovery was achieved. The 59-year-old man presented with myocardial infarction, exacerbated renal insufficiency that required hemodialysis and cardiorespiratory failure complicated by bacterial sepsis. As a result, the patient died. The 83-year-old male patient reporting fever, myalgia, fatigue, cough and dyspnea was admitted to hospital and deceased due to septic shock two days after admission. The 48-year old woman who presented with mild symptoms of the upper respiratory tract infection recovered after two weeks. Symptomatic treatment was used in all the patients. Another male patient (aged 45 years, 8 years after orthotopic heart transplant with no significant comorbidities) was an asymptomatic carrier of SARS-CoV-2 and remained under hospital care.
Conclusions: Of 552 patients after orthotopic heart transplantation, two SARS-CoV-2-related deaths were reported.
Keywords: COVID-19 infection; SARS-CoV-2; immunosuppression; orthotopic heart transplantation.
© National Institute of Public Health – National Institute of Hygiene.
Similar articles
-
Diagnostic Delays for Non-melanoma Skin Cancers in Renal Transplant Recipients during the COVID-19 Pandemic: What is Hiding Behind the Mask?Acta Dermatovenerol Croat. 2021 Jul;29(2):111-113. Acta Dermatovenerol Croat. 2021. PMID: 34477079
-
SARS-CoV-2 / COVID-19 in patients on the Swiss national transplant waiting list.Swiss Med Wkly. 2020 Dec 31;150:w20451. doi: 10.4414/smw.2020.20451. eCollection 2020 Dec 14. Swiss Med Wkly. 2020. PMID: 33382903
-
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0. Trials. 2021. PMID: 33810796 Free PMC article.
-
COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.Mult Scler Relat Disord. 2021 Feb;48:102734. doi: 10.1016/j.msard.2020.102734. Epub 2021 Jan 2. Mult Scler Relat Disord. 2021. PMID: 33429305 Free PMC article. Review.
-
Heart failure and COVID-19.Heart Fail Rev. 2021 Jan;26(1):1-10. doi: 10.1007/s10741-020-10008-2. Heart Fail Rev. 2021. PMID: 32720082 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Medical
Research Materials
Miscellaneous